Oxular Limited, a retinal therapeutics company, has promoted David Fellows, previously Non-Executive Director, as the Chairman of its Board. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a Director.

David Fellows brings a wealth of ophthalmology and organisational leadership experience to Oxular.  He is currently Chief Executive Officer (CEO) of NightstaRx Limited, a private biopharmaceutical company focused on ocular gene therapies.  He was previously Vice President of Johnson & Johnson’s Vision Care Franchise He had also worked for Allergan for 25 years.

Tom Cavanagh, CEO of Oxular Limited said that Fellows’ expertise in the ophthalmic industry will helpOxular building a global ophthalmic franchise developing innovative treatments for retinal diseases. “I would also like to take this opportunity to thank Nigel Pitchford for his invaluable leadership during Oxular’s first year of operations and am pleased that we will continue to benefit from his experience as a Board Director,” said Cavanagh.

David Fellows, Chairman of the Board of Oxular Limited, said: “I am delighted to be appointed Chairman at this exciting time in the Company’s development. Oxular is committed to utilising its expertise to develop and register novel therapies for treating patients with sight-threatening retinal diseases. We have a talented team and I look forward to working with them as we advance our product portfolio.”